Research and Markets (http://www.researchandmarkets.com/research/9zx5dv/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Small-Cell Lung Cancer Overview
- Therapeutics Development
- Pipeline Products for Small-Cell Lung Cancer - Overview
- Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis
- Small-Cell Lung Cancer - Therapeutics under Development by Companies
- Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
- Small-Cell Lung Cancer - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Small-Cell Lung Cancer - Products under Development by Companies
- Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes
- Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
- 3B Pharmaceuticals GmbH
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc.
- Alchemia Limited
- Amgen Inc.
- Andarix Pharmaceuticals, Inc.
- Aposense Ltd.
- Array BioPharma Inc.
- Astellas Pharma Inc.
- BIND Therapeutics, Inc.
- Blend Therapeutics, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Exelixis, Inc.
- F. Hoffmann-La Roche Ltd.
- G1 Therapeutics, Inc.
- Genzyme Corporation
- GlaxoSmithKline Plc
- Karyopharm Therapeutics, Inc.
- Kolltan Pharmaceuticals, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Lindis Biotech GmbH
- MabVax Therapeutics Holdings, Inc.
- MedImmune, LLC
- MEI Pharma, Inc.
- Merck & Co., Inc.
- NanoSmart Pharmaceuticals, Inc.
- Nippon Kayaku Co., Ltd.
- Novartis AG
- Pfizer Inc.
- Polaris Pharmaceuticals, Inc.
- Rexahn Pharmaceuticals, Inc.
- Spectrum Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/9zx5dv/smallcell_lung
View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005409/en/